Thalassaemia: clinical management (Q33953628)

30 July 2017

1 reference

title

Thalassaemia: clinical management (English)

1 reference

30 July 2017

1

Olivieri N

1 reference

30 July 2017

publication date

1 March 1998

1 reference

Best Practice and Research: Clinical Haematology

30 July 2017

published in

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

147-162

1 reference

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Successful use of hydroxyurea in beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Evaluation of a new method of administration of the iron chelating agent deferoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Rapid desensitisation for desferrioxamine anaphylactoid reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Magnetic-susceptibility measurement of human iron stores

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Effects of calcitonin therapy on osteoporosis in patients with thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Hereditary hemochromatosis. Phenotypic expression of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Long-term effect of splenectomy on transfusion requirements in thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Clinical trial of young red cell transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Treatment of beta-thalassemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Chelation therapy in β-thalassemia major. III. The role of splenectomy in achieving iron balance

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Pharmacologic treatment of thalassemia intermedia with hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Brief report: transplantation of cord-blood stem cells into a patient with severe thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

A new approach to neocyte transfusion: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Iron overload cardiomyopathies: new insights into an old disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Laboratory evaluation of a new delivery system to improve patient compliance with chelation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Reduced Left Ventricular Contractile Reserve Identified by Low Dose Dobutamine Echocardiography as an Early Marker of Cardiac Involvement in Asymptomatic Patients with Thalassemia Major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Rapid desensitisation for desferrioxamine anaphylactic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Partial splenectomy in homozygous beta thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Long-term survival in patients with hereditary hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Splenectomy, iron overload and liver cirrhosis in beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Treatment of thalassaemia major with phenylbutyrate and hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Delay in the fetal globin switch in infants of diabetic mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Iron absorption and loading in beta-thalassaemia intermedia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Partial splenic embolisation for hypersplenism of thalassaemia major: five year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Increased transferrin iron saturation in splenectomized thalassaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Interferon therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Desferal (desferrioxamine)—A novel activator of connective tissue-type mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Extended survival of neocytes produced by a new system

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

The impact of neocyte transfusion in the management of thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

7 Increased HbF in adult life

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

Survival and causes of death in thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980073-5

7 January 2021

10.1016/S0950-3536(98)80073-5

Identifiers

DOI

1 reference

30 July 2017

1 reference